Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

39.03 -1.34 (-3.32%)
Streaming Delayed Price Updated: 1:56 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,165
Open 40.37
Bid (Size) 38.87 (100)
Ask (Size) 39.19 (200)
Prev. Close 40.37
Today's Range 39.03 - 40.75
52wk Range 6.710 - 43.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-1.9%
-1.9%
1 Month
-5.9%
-5.9%
3 Month
+36.5%
+36.5%
6 Month
+158.8%
+158.8%
1 Year
+144.7%
+144.7%

More News

Read More
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Via MarketBeat
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
Via Investor's Business Daily
News headline image
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027 ↗
Via Chartmill
News headline image
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 39.03
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 01/08/26 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.